SCH 47687 | 167298-96-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: SCH 47687
• 英文别名: cis-5,6a(R),7,8,9,9a(S)-Hexahydro-2,5-di-methylcyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one；(6aR,9aS)-5,6a,7,8,9,9a-hexahydro-2,5-dimethylcyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one；2,5-dimethyl-(6aR,9aS)-3,4,5,8-tetrahydrocyclopenta[4,5]imidazo[2,1-b]purin-4-one；(11R,15S)-4,8-dimethyl-1,3,5,8,10-pentazatetracyclo[7.6.0.02,6.011,15]pentadeca-2(6),3,9-trien-7-one
• CAS: 167298-96-6
• 化学式: C₁₂H₁₅N₅O
• 分子量: 245.284
• InChiKey: ARPIRHYHUOOCNG-SFYZADRCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  特戊酸氯甲酯 、 SCH 47687 在 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 5,6a(R),7,8,9,9a(S)-Hexahydro-2,5-dimethyl-3-[(trimethylacetoxy)methyl]-cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one
  参考文献：
  名称：

  Polycyclic guanine derivatives

  摘要：

  新颖的多环鸟嘌呤衍生物的化学式为：##STR1## 其中J为氧或硫，R.sup.1为氢，烷基或烷基取代芳基或羟基；R.sup.2为氢，芳基，杂环芳基，环烷基，烷基或烷基取代芳基，杂环芳基，羟基，烷氧基，氨基，单烷基氨基或二烷基氨基，或--(CH.sub.2).sub.m TCOR.sup.20，其中m为1到6的整数，T为氧或--NH--，R.sup.20为氢，芳基，杂环芳基，烷基或烷基取代芳基或杂环芳基；R.sup.3为氢，卤素，三氟甲基，烷氧基，硫烷基，烷基，环烷基，芳基，氨基磺酰基，氨基，单烷基氨基，二烷基氨基，羟基烷基氨基，氨基烷基氨基，羧基，烷氧羰基或氨基羰基或烷基取代芳基，羟基，烷氧基，氨基，单烷基氨基或二烷基氨基；R.sup.a，R.sup.b，R.sup.c和R.sup.d在规范中有定义；n为零或一。化合物的化学式(I)和(I')可用作降压、肌肉松弛和扩张支气管剂。

  公开号：

  US05393755A1
• 作为产物：
  描述：

  6-amino-5-(benzylamino)-3-methylpyrimidine-2,4(1H,3H)-dione 在 palladium dihydroxide 氯化亚砜 、 ammonium formate 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 生成 SCH 47687
  参考文献：
  名称：

  Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity

  摘要：

  Tetracyclic guanines have been shown to be potent and selective inhibitors of the cGMP-hydrolyzing enzymes PDE1 and PDE5. In general, these compounds are inactive or only weakly active as inhibitors of PDE3, which is a major isozyme involved in cAMP hydrolysis. Structure-activity relationships are developed at N-1, C-2, N-3, and N-5 on the core nucleus. Compound 31, with an IC50 of 70 pM, is the most potent inhibitor of PDE1, while 50, with an IC50 of 4 nM, is the most potent inhibitor of PDE5. Compounds 20, 22, 30, and 50 are potent dual inhibitors with IC50 values below 30 nM for both PDE1 and PDE5. Compounds 12, 20, and 28 reduced blood pressure by more than 45 mmHg when administered orally at 10 mg/kg to the spontaneously hypertensive rat (SHR).

  DOI：

  10.1021/jm9608467

文献信息

• Organic compounds
  申请人：INTRA-CELLULAR THERAPIES, INC.

  公开号：US10238660B2

  公开（公告）日：2019-03-26

  The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania, or bipolar disorder.

  本发明涉及一种磷酸二酯酶1（PDE1）抑制剂的新用途，用于治疗精神病、精神分裂症、情感分裂症、精神分裂症、精神病性障碍、妄想性障碍、躁狂症或双相情感障碍。
• Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
  申请人：Intra-Cellular Therapies, Inc.

  公开号：US10285992B2

  公开（公告）日：2019-05-14

  The invention relates to the combination of inhibitors of phosphodiesterase 1 (PDE1) and inhibitors of Neprilysin (NEP) useful for the treatment of certain cardiovascular diseases or related disorders, e.g., hypertension, congestive heart disease, and post-myocardial infarction. In another embodiment, the invention relates to the combination of inhibitors of PDE1 and inhibitors of NEP for the treatment of diseases or disorders characterized by disruption of or damage to various cGMP/PKG mediated pathways in the cardiovascular system (e.g., in cardiac tissue or in arterial smooth muscle).

  本发明涉及磷酸二酯酶1（PDE1）抑制剂和Neprilysin（NEP）抑制剂的组合，用于治疗某些心血管疾病或相关疾病，如高血压、充血性心脏病和心肌梗塞后。在另一个实施方案中，本发明涉及 PDE1 抑制剂和 NEP 抑制剂的组合，用于治疗以心血管系统（如心脏组织或动脉平滑肌）中各种 cGMP/PKG 介导的通路被破坏或损害为特征的疾病或紊乱。
• Combinations of PDE1 inhibitors and NEP inhibitors
  申请人：INTRA-CELLULAR THERAPIES, INC.

  公开号：US11166956B2

  公开（公告）日：2021-11-09

  The invention relates to the combination of inhibitors of phosphodiesterase 1 (PDE1) and inhibitors of Neprilysin (NEP) useful for the treatment of certain cardiovascular diseases or related disorders, e.g., hypertension, congestive heart disease, and post-myocardial infarction. In another embodiment, the invention relates to the combination of inhibitors of PDE1 and inhibitors of NEP for the treatment of diseases or disorders characterized by disruption of or damage to various cGMP/PKG mediated pathways in the cardiovascular system (e.g., in cardiac tissue or in arterial smooth muscle).

  本发明涉及磷酸二酯酶1（PDE1）抑制剂和Neprilysin（NEP）抑制剂的组合，用于治疗某些心血管疾病或相关疾病，如高血压、充血性心脏病和心肌梗塞后。在另一个实施方案中，本发明涉及 PDE1 抑制剂和 NEP 抑制剂的组合，用于治疗以心血管系统（如心脏组织或动脉平滑肌）中各种 cGMP/PKG 介导的通路被破坏或损害为特征的疾病或紊乱。
• PDE1 inhibitors for ophthalmic disorders
  申请人：Davis Robert

  公开号：US11464781B2

  公开（公告）日：2022-10-11

  Compounds that inhibit phosphodiesterase 1 (PDE1) are useful to treat glaucoma or elevated intraocular pressure. The PDE1 inhibitors may be administered as monotherapy or in combination with additional intraocular-pressure lowering agents. In addition, the invention provides ophthalmic compositions comprising PDE 1 inhibitors and optionally one or more additional intraocular pressure-lowering agents. Topical and systemic therapy may be used.

  抑制磷酸二酯酶 1 (PDE1) 的化合物可用于治疗青光眼或眼压升高。PDE1 抑制剂可作为单药或与其他降低眼压的药物联合使用。此外，本发明还提供了包含 PDE 1 抑制剂和一种或多种额外的眼压降低剂的眼科组合物。可采用局部和全身疗法。
• Preparation of Guanine PDE Inhibitors:  Development of the Common Synthetic Route Strategy. A Case Study
  作者：D. Gala、D. DiBenedetto、G. Gloor、J. Jenkins、M. Kugelman、D. Maloney、A. Miller

  DOI：10.1021/op030212r

  日期：2004.5.1

  A single synthetic route, called the chloropurine route, capable of quickly delivering initial kilogram quantities of several chiral as well as achiral guanine phosphodiesterase inhibitors of increasing complexity is described. During the course of this work, unraveling the formation mechanism of chloropurines allowed for the scale-up of the key intermediates. The mechanism for the cyclization of the chiral five-membered amino alcohols and its implication on the enantiomeric purity needed for this step are also described.